Syk

BI 894416 is a selective inhibitor of spleen tyrosine kinase (SYK), a key regulator involved in various immune responses. This compound is particularly relevant for studying the pathophysiology of severe asthma, making it valuable in the development of therapeutic strategies. Additionally, BI 894416 features a deuterium-labeled derivative, which serves as an internal standard in bioanalytical applications, enhancing the accuracy of quantitative assessments in research settings.

(rel)-PRT062607 is a selective inhibitor of Syk kinase, demonstrating high potency with an IC50 value of 1-2 nM. This compound exhibits over 80-fold selectivity against related kinases such as Fgr, Lyn, FAK, Pyk2, and Zap70. Its specificity makes it a valuable tool for studying Syk-mediated pathways in various biological contexts and offers potential applications in autoimmune and inflammatory disease research.

Syk-IN-7 is a selective inhibitor of spleen tyrosine kinase (SYK). It demonstrates significant inhibition of SYK activity, thereby impacting B-cell receptor signaling pathways and immune responses. This compound is valuable for studying the roles of SYK in immunological research and potential therapeutic applications in autoimmune diseases and lymphoid malignancies.

Syk-IN-2 is a selective inhibitor of spleen tyrosine kinase (Syk), a vital signaling molecule in various hematopoietic cells. Its inhibition modulates immune responses and has been implicated in the treatment of autoimmune diseases and certain cancers. This compound serves as a valuable tool for researchers investigating Syk-related pathways and potential therapeutic interventions.

NMS-0963 is a potent inhibitor of spleen tyrosine kinase (SYK), exhibiting an oral bioavailability and an IC50 value of 3 nM. This compound effectively inhibits the proliferation of BaF3-TEL/SYK cell lines at a concentration of 27 nM, making it a valuable tool for investigating SYK-related pathways in various biological contexts and potential therapeutic applications in diseases involving SYK dysregulation.

BI1002494 is a selective inhibitor of spleen tyrosine kinase (SYK) with oral bioavailability. It demonstrates potent inhibitory activity with an IC50 of 115 nM against high-affinity IgE receptor-mediated degranulation in mast cells and basophils. This compound is a valuable tool for studying immune responses and can be applied in a variety of immunology research applications.

Type-II-IN-1 is a potent type II inhibitor of spleen tyrosine kinase (Syk), exhibiting an IC50 value of 2.1 nM. It specifically interacts with the DFG-out conformation of Syk, making it a valuable tool for the study of immunological processes. This compound is particularly relevant for research applications related to asthma and other immune-related disorders.

Syk-IN-13 is a selective inhibitor of Spleen tyrosine kinase (Syk). It has demonstrated significant biological activity in modulating immune responses and inflammatory pathways, making it a valuable tool for researching conditions such as rheumatoid arthritis and systemic lupus erythematosus. This compound allows for the exploration of Syk's role in various cellular processes, highlighting its potential as a therapeutic target in autoimmune diseases.

Syk-IN-11 is a selective inhibitor of Spleen tyrosine kinase (Syk) with a reported IC50 of 13 nM. This compound demonstrates significant biological activity and has applications in the research of autoimmune disorders such as arthritis, as well as hematological malignancies like chronic lymphocytic leukemia. Its role in modulating Syk signaling pathways makes it a valuable tool for elucidating disease mechanisms and developing potential therapeutic strategies.